Advancing plant-derived therapeutics for HBV-associated liver disease
Curaem Pharmaceuticals is developing a standardized plant-derived investigational candidate through a reverse-pharmacology pathway, with a focus on HBV-associated liver injury, fibrosis, cirrhosis, and chronic liver disease progression.
A silent progression that continues to demand better options.
HBV remains a major global liver disease burden, with WHO-estimated hundreds of millions affected globally and liver-related complications including cirrhosis and hepatocellular carcinoma.
people living with hepatitis B globally
HBV-related deaths annually
unmet need across fibrosis, cirrhosis, and HCC
Source: World Health Organization, Global Hepatitis Report (2024 update).
Bringing pharmaceutical discipline to medicinal plant discovery.
Curaem's mission is to combine botanical knowledge, controlled sourcing, phytochemical standardization, biological validation, and clinical development planning within a modern pharmaceutical framework.
Nature-derived discovery
Starting from medicinal plant knowledge with therapeutic potential.
Pharmaceutical standardization
Controlled cultivation, marker-component tracking, and quality-focused formulation.
Development pathway
Advancing toward clinical validation through a staged, regulated development process.
Future access planning: preparing for regional market access and strategic partnerships, subject to clinical and regulatory milestones.
A disciplined path from plant to pharmaceutical candidate.
Reverse Pharmacology
Beginning from medicinal plant knowledge, then applying modern validation.
Standardized Botanical Inputs
Authentication, phytochemical analysis, marker components, and quality control.
Multi-Modal Validation
In-vitro anti-HBV assays, hepatoprotective models, antioxidant activity, cytotoxicity screening, molecular docking, and biomarker evaluation.
Current stage: preclinical research and clinical-readiness planning.
Discovery / Proof of Concept
Preclinical Research & Fingerprinting
Clinical Research
Regulatory, Commercialization & Post-Market Safety
Curaem is seeking aligned capital and strategic support to complete the next phase of preclinical development, prepare clinical protocols, and build production-readiness infrastructure.
Leadership combining scientific validation, business execution, and strategic capital experience.
Curaem is led by a multidisciplinary team combining biomedical research, entrepreneurial execution, investment experience, and strategic development capability.
Dr Ashok Gnanasekaran
Associate Professor and researcher supporting Curaem's preclinical research, biological validation, and scientific development pathway.
Nicholas Goh
Executive and entrepreneur supporting Curaem's business development, investor engagement, and operational execution.
Satia Narjadin
Serial entrepreneur and VC investor supporting strategic growth, capital planning, and partnership development.
Scientific, clinical, regulatory, and manufacturing advisors to be announced as the program advances.
Funding the next stage of a differentiated liver disease program.
Curaem is opening qualified investor conversations to support clinical-readiness, regulatory planning, standardized production capability, and controlled cultivation infrastructure.
Qualified parties may request diligence access under NDA.
Curaem's scientific, clinical, manufacturing, and regulatory documentation is provided only to qualified investors and partners through appropriate legal and diligence processes.
Investigational candidate. Not approved for sale or patient use.